Pteroylmonoglutamic Acid Hydrolase G2
Toxic Encephalopathy
Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
University College, London
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00727831CT.gov Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | — | Completed | — | — | — |
NCT00018967CT.gov Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Toxic Encephalopathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pteroylmonoglutamic Acid Hydrolase G2 (this asset) | University College, London | P1/2 | CCC · 52 |
| Eribulin Monomethanesulfonate | Oncologia Medica dell'Ospedale Fatebenefratelli | P4 | BB |
| Procarbazine | Radiation Therapy Oncology Group | P2 | BB |
| Carboplatin | Alliance for Clinical Trials in Oncology | P3 | BB |
| Amitriptyline | Alliance for Clinical Trials in Oncology | P3 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Alliance for Clinical Trials in Oncology | P3 | BB |
| Fluorouracilum | Alliance for Clinical Trials in Oncology | P3 | BB |
| Amifostine | M.D. Anderson Cancer Center | P3 | BB |
| Methotrexate | Radiation Therapy Oncology Group | P2 | BB |
+38 more in the Toxic Encephalopathy cohort
Other indications for Pteroylmonoglutamic Acid Hydrolase G2
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P3 | BB · 64 |
| Lymphoma | — | P2 | B · 59 |
| Mucositis | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Eribulin MonomethanesulfonateOncologia Medica dell'Ospedale FatebenefratelliBB
- ProcarbazineRadiation Therapy Oncology GroupBB
- CarboplatinAlliance for Clinical Trials in OncologyBB
- AmitriptylineAlliance for Clinical Trials in OncologyBB
- (±)-2-(O-Chlorophenyl)-2-(Methylamino)CyclohexanoneAlliance for Clinical Trials in OncologyBB
Citation
Floatz Terminal. Pteroylmonoglutamic Acid Hydrolase G2 in Toxic Encephalopathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pteroylmonoglutamic-acid-hydrolase-g2-toxic-encephalopathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →